[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376598-105":59,"doc-detail-376598-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","survival-in-non-small-cell-lung-cancer-patients-with-versus-without-prior-cancer","Survival in non-small cell lung cancer patients with versus without prior cancer","","Survival outcomes in newly diagnosed non-small cell lung cancer (NSCLC) were assessed by examining whether prior cancer history changes all-cause mortality risk. A retrospective cohort study used Japan population-based cancer registry data linked with administrative claims, covering 9103 patients aged 15–84 diagnosed from 2010–2015. Cox proportional hazards models estimated hazard ratios across NSCLC stages and diagnostic time intervals. Overall, prior cancer showed a non-significant mortality increase, yet higher hazard emerged at 3- and 5-year intervals, while advanced-stage patients did not show interval-linked risk. Smoking-related and poorer-prognosis prior cancers predicted worse survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-in-non-small-cell-lung-cancer-patients-with-versus-without-prior-cancer/376598/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-in-non-small-cell-lung-cancer-patients-with-versus-without-prior-cancer/376598.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How was the study designed to compare NSCLC mortality risk with and without prior cancer?","Question",{"text":113,"@type":114},"The study used a multicenter retrospective cohort design and linked population-based cancer registry data with administrative claims data to compare all-cause mortality between patients with and without prior cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Did prior cancer increase mortality risk overall in newly diagnosed NSCLC patients?",{"text":118,"@type":114},"Overall prior cancer had a non-significant mortality hazard ratio (HR 1.07; 95% CI 0.97–1.17).",{"name":120,"@type":111,"acceptedAnswer":121},"How did the impact of prior cancer vary by diagnostic time interval?",{"text":122,"@type":114},"A significantly higher mortality hazard was observed for diagnostic time intervals of 3 years (HR 1.23) and 5 years (HR 1.18), but not for longer intervals.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},376598,1790269498,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSurvival in non‑small cell lung cancer patients  \nwith versus without prior cancer  \nAkira Sato1,2, Toshitaka Morishima1*, Masato Takeuchi2, Kayo Nakata1, Koji Kawakami2,3 & Isao Miyashiro1,3  \nClinical trials on cancer treatments frequently exclude patients with prior cancer, but more evidence is needed to understand their possible effects on outcomes. This study analyzed the prognostic impact of prior cancer in newly diagnosed non‑small cell lung cancer (NSCLC) patients while accounting for various patient and cancer characteristics. Using population‑based cancer registry data linked with administrative claims data, this retrospective cohort study examined patients aged 15–84 years diagnosed with NSCLC between 2010 and 2015 in Japan. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of all‑cause mortality in patients with versus without prior cancer. The analysis was stratified according to NSCLC stage and diagnostic time intervals between prior cancers and the index NSCLC. We analyzed 9103 patients (prior cancer:  \n1416 [15.6%]; no prior cancer: 7687 [84.4%]). Overall, prior cancer had a non‑significant mortality HR of 1.07 (95% CI: 0.97–1.17). Furthermore, prior cancer had a significantly higher mortality hazard for diagnostic time intervals of 3 years (HR: 1.23, 95% CI: 1.06–1.43) and 5 years (1.18, 1.04–1.33), but not for longer intervals. However, prior cancer in patients with more advanced NSCLC did not show a higher mortality risk for any diagnostic time interval. Smoking‑related prior cancers and prior cancers with poorer prognosis were associated with poorer survival. NSCLC patients with prior cancer do not have an invariably higher risk of mortality, and should be considered for inclusion in clinical trials depending on their cancer stage.  \nAbbreviations  \nHR Hazard ratio  \nCI Confidence interval  \nCCI Charlson comorbidity index  \nECOG-PS Eastern Cooperative Oncology Group-Performance Status ICD-10 International classification of diseases, tenth revision NSCLC Non-small cell lung cancer  \nOCR Osaka Cancer Registry  \nSEER Surveillance, epidemiology, and end results MLT Mean lead times  \nThe improved survival of cancer patients has inadvertently led to an increase in the number of persons with multiple primary cancers1–4. Despite the growing prevalence of newly diagnosed cancer patients with a history of cancer (e.g., 18.7% in the US and 11.1% in Japan)4,5, such patients are often excluded from clinical trials due to concerns that their presence may unduly affect outcomes and distort conclusions6–11. Overall, 80% of trials excluded lung cancer patients with prior cancer. The estimated proportion of patients with lung cancer excluded because of prior cancer ranged from 0 to 18%7. The omission of these patients may limits the generalizability of findings from clinical trials and observational research, resulting in a dearth of evidence on new treatment modalities for cancer survivors6–11.  \nPrevious studies have produced conflicting findings on the prognostic impact of prior cancer in newly diagnosed lung cancer patients. While some studies have reported that prior cancer did not reduce survival in  \n1Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan. 2Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, Japan. 3These authors contributed equally: Koji Kawakami and Isao  \nMiyashiro.*[email: morishima.t@oici.jp](email: morishima.t@oici.jp)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nearly-stage, locally advanced, or advanced lung cancer patients12–14; others have noted that the prognostic impact of prior cancer can vary according to lung cancer stage15–18. In contrast, several studies have indicated that prior","cbCaig84KOigTi5z","https://ap.wps.com/l/cbCaig84KOigTi5z","pdf",1307899,11,"English","# Materials and methods\n## Study design and data sources","[{\"question\":\"How was the study designed to compare NSCLC mortality risk with and without prior cancer?\",\"answer\":\"The study used a multicenter retrospective cohort design and linked population-based cancer registry data with administrative claims data to compare all-cause mortality between patients with and without prior cancer.\"},{\"question\":\"Did prior cancer increase mortality risk overall in newly diagnosed NSCLC patients?\",\"answer\":\"Overall prior cancer had a non-significant mortality hazard ratio (HR 1.07; 95% CI 0.97–1.17).\"},{\"question\":\"How did the impact of prior cancer vary by diagnostic time interval?\",\"answer\":\"A significantly higher mortality hazard was observed for diagnostic time intervals of 3 years (HR 1.23) and 5 years (HR 1.18), but not for longer intervals.\"}]","Survival in non-small cell lung cancer patients with versus without prior cancer | PDF",1790220148,28]